Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir–Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report
- 8 October 2024
- journal article
- research article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 40 (10) , 555-556
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and OpportunitiesClinical Infectious Diseases, 2023
- Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority StudyClinical Infectious Diseases, 2023
- Cabotegravir–rilpivirine treatment initiation in a nonvirologically suppressed patientAIDS, 2022
- Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR studyThe Lancet HIV, 2021